St. Louis Reporter

Medical Professor: Federal drug discount program that serves 84 MO hospitals has become ‘a lucrative space where profits often outweigh patients’

By St. Louis Reporter News Service | Dec 18, 2024

An assistant professor at Tulane University School of Medicine said the federal 340b drug discount program has “strayed from its original purpose” and is now “a case study in how good intentions can go astray.”

Health Policy Analyst: Inflation Reduction Act’s drug price provision could mean job losses in cities like St. Louis

By St. Louis Reporter News Service | May 11, 2024

An American Enterprise Institute (AEI) health care policy analyst said that a drug price provision in the “Inflation Reduction Act” (IRA) could lead to job losses in areas, such as St. Louis, in which biopharma companies are developing small molecule drugs.

5 St. Louis biopharma companies could be negatively impacted by Inflation Reduction Act drug provision

By St. Louis Reporter News Service | Apr 24, 2024

A provision of the “Inflation Reduction Act” (IRA) could threaten investments in "small molecule" drug development, said the Missouri-based president of The Latino Coalition.

Taxpayers Protection Alliance President: St. Louis tourism threatened by Sen. Hawley’s credit card bill

By St. Louis Reporter News Service | Apr 14, 2024

New credit card regulations sponsored by U.S. Sen. Josh Hawley (R-Mo.) could threaten Missouri’s $19.9 billion tourism industry, said David Williams, president of the Taxpayers Protection Alliance (TPA).